This is a medication used to treat HIV infection. It works by blocking a specific protein on the surface of HIV, preventing the virus from entering your cells. It's usually taken as a pill.
Every report comes from a Lived member, sent anonymously.
Have you tried Selzentry (Maraviroc) for HIV Infection?
Maraviroc, sold in the US as Selzentry and also available as a generic, is a prescription medicine for HIV (human immunodeficiency virus). It treats HIV-1, the main type of HIV, in adults and in children who weigh at least 2 kg (about 4.4 pounds), always as part of a combination with other HIV medicines, never on its own. It works against only one kind of HIV. To get into immune cells, HIV latches onto a docking protein called a co-receptor, and different strains use different ones: CCR5, CXCR4, or both. Maraviroc blocks only CCR5, so before it is prescribed, a blood test called a tropism test has to show that a person's virus uses CCR5 alone. It is not recommended when the virus uses CXCR4 or both co-receptors. Its main evidence comes from people whose HIV had already been treated with, or become resistant to, several other drug classes. In that group, adding maraviroc to a rebuilt regimen substantially improved control of the virus. Most people starting HIV treatment today take once-daily regimens built around a newer drug class called integrase inhibitors, which need no tropism test, so maraviroc tends to be a more specialized choice.
HIV infects CD4 cells, the white blood cells that coordinate the immune response. To enter one, the virus first attaches to the CD4 protein on the cell surface and then needs a second contact point, the co-receptor. Maraviroc binds to the CCR5 co-receptor on the person's own cells and holds it in a shape the virus cannot use. That stops CCR5-using HIV at the door, before it can get inside and make copies of itself. This sets maraviroc apart from most HIV medicines, which act on the virus's own enzymes. It also explains its main limitation: virus that enters through CXCR4 is not blocked. Small amounts of CXCR4-using virus that the screening test missed can grow out and cause treatment to fail, which is one reason the other medicines in the combination matter.
Maraviroc is taken by mouth twice a day, with or without food. Tablets should be swallowed whole, not chewed. An oral solution is available for children who cannot reliably swallow tablets, and children's doses are based on body weight. The dose depends heavily on what else a person takes. Some drugs slow the body's breakdown of maraviroc and call for a lower dose, including many HIV protease inhibitors and certain antibiotics and antifungal medicines. Others speed it up and call for a higher dose, such as efavirenz (an older HIV medicine), rifampin (a tuberculosis antibiotic) and some seizure medicines. Kidney function can also change the dose. Any change to the rest of the HIV regimen or to other prescriptions should be checked with the prescriber or pharmacist first. Taking doses on schedule matters, because missed doses can let the virus develop resistance. If a dose is missed, take it as soon as you remember, but never take two doses at the same time.
In clinical trials, most side effects were mild to moderate. Those reported more often than with placebo included colds and other upper respiratory infections, cough, fever, rash and dizziness. Some people feel lightheaded when they stand up, because maraviroc can lower blood pressure. If that happens, avoid driving or operating machinery and let the care team know. The most important serious risk is liver injury, which is the subject of the label's boxed warning, its strongest type. It can be life-threatening and may begin with a severe rash or an allergic-type reaction, such as fever, before the liver problem shows itself. Reported cases appeared about a month after starting. Stop taking maraviroc and call the prescriber right away for an itchy rash, yellowing of the skin or the whites of the eyes, dark or tea-colored urine, vomiting, or pain or tenderness on the right side of the stomach area. Rarely, maraviroc causes severe skin reactions. A rash with fever, blisters, mouth sores, red eyes or swelling of the face or lips is also a reason to stop the medicine and contact the care team right away, because delay in stopping can make these reactions more dangerous.
Because so many medicines change maraviroc levels, the prescriber and pharmacist need a complete list of everything you take, including over-the-counter products and supplements. St. John's wort, an herbal supplement used for mood, should not be combined with maraviroc: it can lower maraviroc levels enough for the virus to rebound and become resistant. Severe kidney disease, including dialysis, needs particular care. In that situation maraviroc must not be taken with strong drugs that raise or lower its levels, and even without them it is considered only when no other option fits, because higher drug levels raise the risk of blood pressure dropping on standing. Tell the prescriber about any liver disease, including hepatitis B or C, since liver monitoring may need to be closer. Heart disease, low blood pressure and blood pressure medicines also matter. In trials of people with previous HIV treatment, a small number taking maraviroc had heart problems such as heart attacks, mostly people who already had heart disease or its risk factors, and how much the drug contributed is not known. Information on maraviroc in pregnancy is limited, and a pregnancy registry collects outcomes for people who take it. The US label advises against breastfeeding while taking it. Anyone who is pregnant, planning a pregnancy or feeding an infant should talk through the options with the HIV care team.
Before starting, expect blood tests: the tropism test, liver tests (the liver enzymes ALT and AST, alanine and aspartate aminotransferase, plus bilirubin) and the usual HIV measurements. Two numbers are followed throughout HIV treatment. The viral load is the amount of HIV in the blood, which treatment aims to push very low. The CD4 count shows how well the immune system is recovering. In the main trials of people with heavily treated HIV, about 45% reached a viral load below 50 copies per milliliter at 48 weeks with maraviroc added, compared with fewer than 1 in 5 on the other medicines alone. How well it works depends a great deal on the strength of the rest of the combination. Liver tests may be repeated during treatment and are checked promptly if a rash or other warning signs develop. As treatment starts working and the immune system recovers, it can occasionally react strongly to an infection that was already present in the body, so new symptoms in the first months are worth reporting. Maraviroc does not cure HIV. It is a long-term, twice-daily medicine, and stopping it or changing doses should be done only with the care team, because gaps in treatment risk resistance. If the virus stops responding, one known cause is the growth of CXCR4-using virus, which maraviroc cannot block.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Selzentry (Maraviroc), what you've noticed, or ask the community a question.